Inhibiting the a4 subunit of the integrin heterodimers a4b1 and a4b7 with the mab natalizumab is an effective treatment of multiple sclerosis (MS). Which of the two a4 heterodimers is involved in disease pathogenesis has, however, remained controversial. Whereas the development of experimental autoimmune encephalomyelitis (EAE), an animal model of MS, is ameliorated in b7-integrin-deficient C57BL/6 mice, neutralizing antibodies against the b7-integrin subunit or the a4b7-integrin heterodimer fail to interfere with EAE pathogenesis in the SJL mouse. To facilitate a4b7-integrin-mediated immune-cell trafficking across the blood-brain barrier (BBB), we established transgenic C57BL/6 mice with endothelial cell-specific, inducible expression of the a4b7-integrin ligand mucosal addressin cell adhesion molecule (MAdCAM)-1 using the tetracycline (TET)-OFF system. Although TET-regulated MAdCAM-1 induced a4b7-integrin mediated interaction of a4b7 1 /a4b1 À T cells with the BBB in vitro and in vivo, it failed to influence EAE pathogenesis in C57BL/6 mice. TET-regulated MAdCAM-1 on the BBB neither changed the localization of central nervous system (CNS) perivascular inflammatory cuffs nor did it enhance the percentage of a4b7-integrin 1 inflammatory cells within the CNS during EAE. In conclusion, our study demonstrates that ectopic expression of MAdCAM-1 at the BBB does not increase a4b7-integrin-mediated immune cell trafficking into the CNS during MOG aa35-55 -induced EAE.Keywords: a4-integrins . Blood-brain barrier . Experimental autoimmune encephalomyelitis . Leukocyte trafficking . Mucosal addressin cell adhesion molecule-1
Supporting Information available online
IntroductionInhibiting the a4 subunit of the integrin heterodimers a4b1 and a4b7 with the mab natalizumab has proven to be an effective treatment of multiple sclerosis (MS). Natalizumab inhibits the adhesion of circulating T cells to the inflamed blood-brain barrier (BBB) and therefore blocks further recruitment of autoaggressive T cells into the central nervous system (CNS) of MS patients [1]. Natalizumab was developed based on the observation that blocking a4-integrins inhibits experimental autoimmune encephalomyelitis (EAE), an animal model for MS, by interfering with immune cell trafficking across the BBB into the CNS (summarized in [2]). It has been generally assumed that a4b1-integrin and not a4b7-integrin is targeted by the antibody treatment in MS and Studies specifically addressing the role of a4b7-integrin in EAE pathogenesis have produced inconsistent results. When blocking a4b7-integrin or b7-integrins with neutralizing antibodies our laboratory found no influence on the development of EAE in the SJL mouse, demonstrating that a4b7-integrin is not required for disease pathogenesis [3]. In apparent contrast to our findings are reports demonstrating that b7-integrin-deficient C57BL/6 mice are partially resistant to EAE transferred by the extremely high number of 6 Â 10 8 MOG-specific T-cell blasts [14]. In the same EAE model, neutralizing antibodies aga...